Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain

  • STATUS
    Recruiting
  • End date
    Dec 28, 2023
  • participants needed
    808
  • sponsor
    Vertanical GmbH
Updated on 29 September 2021

Summary

Analysis of the efficacy, maintenance of efficacy, long-term safety, and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Description

The study is divided into four phases: Phase A, B, C and D. All patients who have completed Phase A and for whom the investigator considers further participation to be safe shall begin Phase B. Phases C and D run in parallel, so that patients who have completed Phase B and for whom the investigator considers further participation to be safe can be assigned to one of the two phases.

Phases A and D follow a double-blind, placebo-controlled design, while Phase B and C have an open-label design.

The main goal of Phase A is to demonstrate the efficacy of VER-01 compared to placebo. In Phase B and C the main goal is the investigation of long-term safety of VER-01. In Phase D the primary objective is to demonstrate the maintenance of efficacy of VER-01 on a placebo-controlled basis.

The potential for dependence and abuse will be analyzed in all Phases (A,B,C,D), while the effect of abrupt drug withdrawal of VER-01 will be analyzed in Phase C and D.

Details
Condition Chronic Non-specific Low Back Pain
Treatment Placebo, VER-01
Clinical Study IdentifierNCT04940741
SponsorVertanical GmbH
Last Modified on29 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male and female patients (18 years and older)
Chronic (for at least three months) non-specific pain in the lower back (between the lower ribcage and the gluteal folds)
Pain intensity on average at least 4 points on an 11-point NRS (one month before the start of the study)
Patients with indicated drug treatment where previous optimised treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance
Willingness of both men and women to use a reliable method of contraception during study participation and for three months after taking the last dose of the IMP
Signed patient information and informed consent form is available
Understanding of the German language, ability to give consent and compliance
The patient has understood the instructions to avoid changes in lifestyle and dietary habits
The patient has understood the principle of the patient diary and gives their consent to keep it as instructed
Additional for Phase A
a1. Pain intensity averaged at least 4 points on an 11-point NRS (there must
be at least 5 pain intensity readings in the morning from the run-in phase)
a2. Willingness not to take any analgesic medication (non-opioid and opioid
analgesics as well as adjuvant analgesics) during participation in study Phase
A (except rescue medication)
a3. Willingness to continue a current non-drug therapy unchanged as planned
during participation in Phase A
Additional for Phase B
b1. Previous and complete participation in Phase A until and including Visit
A6
b2. Patient wishes to participate voluntarily in the long-term study
b3. From the investigator's point of view, further participation is considered
medically safe
b4. Willingness not to take any additional analgesic medication (non-opioid
and opioid analgesics as well as adjuvant analgesics) during the last three
weeks of study Phase B (except rescue medication)
Additional for Phase C
c1. Previous and complete participation in Phase B until and including Visit
B10
c2. Patient wishes to participate voluntarily in the long-term study
c3. From the investigator's point of view, further participation is considered
medically safe
Additional for Phase D
d1. Previous and complete participation in Phase B until and including Visit
B10 (patients received Ver-01 for 26 weeks)
d2. Patient has experienced a pain score improvement of at least 30% in
treatment Phase B (mean value of the study week 43 compared to the mean value
of the run-in phase, there must be at least four values from study week 43 and
five values from the run-in phase)
d3. Patient wishes to participate voluntarily in the study
d4. From the investigator's point of view, further participation is considered
medically safe
d5. Willingness not to take any analgesic medication (non-opioid and opioid
analgesics as well as adjuvant analgesics) during participation in study Phase
D (except rescue medication)
d6. Willingness to continue a current non-drug therapy unchanged as planned
during study

Exclusion Criteria

Professional groups for which the ability to operate machinery and drive vehicles is the primary activity (including truck, bus and forklift drivers, pilots)
Alcohol/drug/medication abuse and previous or current intake of methadone in the patient's medical history or suspected by the investigator
Intake of analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) within seven days prior to the start of the study
Taking cannabis-based products within 30 days prior to the start of the study
HIV, dementia (which impairs the assessment of symptoms)
Severe forms of the following diseases: Anaemia,hematological/autoimmune/endocrinal/ renal/hepatic/respiratory/cardiovascular or gastrointestinal diseases, symptomatic peripheral vascular diseases
Cardiovascular event in the past three months, poorly managed high blood pressure, untreated hypothyroidism, patients with Crigler-Najjar syndrome or Rotor syndrome, surgery within the past two months
Severe mental illnesses (e.g. psychosis, schizophrenia, bipolar disorder), severe depression that is not due to the chronic non-specific low back pain, or individuals at risk of suicide (examined using the MINI questionnaire)
Severe mental illness (psychosis, schizophrenia, bipolar disorder, severe depression, anxiety disorder) in a first-degree relative (parents and children); suicide in a first-degree relative (parents and children)
Patients with an active cancer or tumor-related pain or severe pain due to physical injury
Other painful comorbidities, excluding low back pain, that could interfere with the patient's evaluation during the study or the assessment of pain
Well-known strong adverse events in connection with cannabis consumption before the start of the study
Known allergy to cannabis and/or sesame seeds and products derived from them
Known hypersensitivity to the ingredients of the rescue medication
Planned blood donation, planned sperm or egg donation, planned freezing of eggs or sperm
Pregnancy, breastfeeding, desire to have children (within the next 20 months)
Participation in another clinical trial within the past 30 days before the start of the study
Inability to give consent, care dependency, patient has a legal guardian/caregiver, or is immobile
The patient is in need of special protection (e.g., incarcerated; institutionalized by a court or judicial authority; in a dependent or employment relationship with the sponsor, an external service provider of the sponsor (who is involved in the study conduct), the investigator, or the study site)
Additional for Phase A
a1. In the case of a current non-drug therapy (e.g. physical or behavioural
therapy, acupuncture,massage, thermotherapy), which significantly modulates
the perception of pain, it was not maintained unchanged for at least eight
weeks prior to study participation in Phase A
Additional for Phase D
d1. Intake of additional analgesic medication (non-opioid and opioid
analgesics as well as adjuvant analgesics) within 21 days prior to the start
of study Phase D (except rescue medication)
d2. In the case of a current non-drug therapy (e.g. physical or behavioural
therapy, acupuncture,massage, thermotherapy) that significantly modulates the
perception of pain, it was not maintained unchanged for at least nine weeks
prior to the start of study Phase D
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note